Proteome Characterization of BALF Extracellular Vesicles in Idiopathic Pulmonary Fibrosis: Unveiling Undercover Molecular Pathways.
Aged
Biomarkers
Bronchoalveolar Lavage Fluid
Chromatography, Liquid
Disease Susceptibility
Electrophoresis, Gel, Two-Dimensional
Extracellular Vesicles
/ metabolism
Female
Humans
Idiopathic Pulmonary Fibrosis
/ etiology
Male
Middle Aged
Proteome
Proteomics
/ methods
Signal Transduction
Tandem Mass Spectrometry
BALF
EVs
IPF
shotgun proteomics
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
27 May 2021
27 May 2021
Historique:
received:
23
04
2021
revised:
24
05
2021
accepted:
24
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
24
6
2021
Statut:
epublish
Résumé
In the longtime challenge of identifying specific, easily detectable and reliable biomarkers of IPF, BALF proteomics is providing interesting new insights into its pathogenesis. To the best of our knowledge, the present study is the first shotgun proteomic investigation of EVs isolated from BALF of IPF patients. Our main aim was to characterize the proteome of the vesicular component of BALF and to explore its individual impact on the pathogenesis of IPF. To this purpose, ultracentrifugation was chosen as the EVs isolation technique, and their purification was assessed by TEM, 2DE and LC-MS/MS. Our 2DE data and scatter plots showed considerable differences between the proteome of EVs and that of whole BALF and of its fluid component. Analysis of protein content and protein functions evidenced that EV proteins are predominantly involved in cytoskeleton remodeling, adenosine signaling, adrenergic signaling, C-peptide signaling and lipid metabolism. Our findings may suggest a wider system involvement in the disease pathogenesis and support the importance of pre-fractioning of complex samples, such as BALF, in order to let low-abundant proteins-mediated pathways emerge.
Identifiants
pubmed: 34071777
pii: ijms22115696
doi: 10.3390/ijms22115696
pmc: PMC8199247
pii:
doi:
Substances chimiques
Biomarkers
0
Proteome
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Regione Toscana
ID : B66J18000080002
Références
Pulm Pharmacol Ther. 2020 Oct;64:101941
pubmed: 32896631
Cardiovasc Hematol Disord Drug Targets. 2013 Dec;13(3):197-207
pubmed: 24479719
Inflammation. 2020 Feb;43(1):1-7
pubmed: 31297749
Nat Rev Drug Discov. 2020 Jan;19(1):57-75
pubmed: 31548636
Inflammation. 2008 Oct;31(5):351-4
pubmed: 18784990
PLoS One. 2013 Oct 25;8(10):e77706
pubmed: 24204926
Proteomics Clin Appl. 2014 Oct;8(9-10):737-47
pubmed: 24616423
J Mol Cell Cardiol. 2016 Aug;97:153-61
pubmed: 27167848
J Cyst Fibros. 2019 Jul;18(4):501-506
pubmed: 30348611
FASEB J. 2017 Nov;31(11):4745-4758
pubmed: 28701304
Respir Med. 2012 Apr;106(4):571-80
pubmed: 22209187
Respir Physiol Neurobiol. 2009 Jul 31;167(3):261-7
pubmed: 19464392
Diabetes Metab Res Rev. 2020 Feb;36(2):e3210
pubmed: 31351021
Int J Mol Sci. 2020 Aug 07;21(16):
pubmed: 32784632
Purinergic Signal. 2016 Jun;12(2):191-7
pubmed: 26847815
Proteomics Clin Appl. 2020 Jan;14(1):e1900077
pubmed: 31631581
Int J Chron Obstruct Pulmon Dis. 2020 May 05;15:973-980
pubmed: 32440109
Ann Transl Med. 2020 Feb;8(4):132
pubmed: 32175425
J Breath Res. 2016 Apr 15;10(2):026007
pubmed: 27082636
Eur Respir J. 2013 Sep;42(3):802-25
pubmed: 23397306
Am J Respir Crit Care Med. 2018 Dec 15;198(12):1527-1538
pubmed: 30044642
Front Pharmacol. 2018 Jan 31;9:54
pubmed: 29445342
Lung. 2000;178(5):271-93
pubmed: 11147312
Methods Mol Biol. 2017;1660:221-232
pubmed: 28828660
Proteomics Clin Appl. 2009 Sep;3(9):1044-51
pubmed: 21137005
J Proteomics. 2013 May 27;83:60-75
pubmed: 23528693
J Proteome Res. 2015 Feb 6;14(2):1238-49
pubmed: 25541672
Gut. 2019 Mar;68(3):522-532
pubmed: 30301768
Thorax. 2021 Jan;76(1):73-82
pubmed: 33214245
Curr Opin Pulm Med. 2009 Sep;15(5):470-8
pubmed: 19593140
J Control Release. 2019 Jan 28;294:43-52
pubmed: 30529727
Eur Respir J. 2020 Mar 26;55(3):
pubmed: 31949113
CSH Protoc. 2006 Nov 01;2006(6):
pubmed: 22485992
J Proteomics. 2018 Aug 15;185:1-7
pubmed: 30032860
Int J Mol Sci. 2020 Jul 30;21(15):
pubmed: 32751630
Proteomics. 2005 Jul;5(10):2612-8
pubmed: 15924291
J Negat Results Biomed. 2017 Mar 1;16(1):4
pubmed: 28245857
Curr Protoc Cell Biol. 2006 Apr;Chapter 3:Unit 3.22
pubmed: 18228490
Dis Model Mech. 2019 May 15;12(5):
pubmed: 31036697
Am J Respir Crit Care Med. 2019 Mar 1;199(5):622-630
pubmed: 30141961
Cells. 2019 Jul 15;8(7):
pubmed: 31311206
Biochem J. 2001 Apr 1;355(Pt 1):123-9
pubmed: 11256956
Proteomics. 2005 Apr;5(5):1423-30
pubmed: 15761959
Life Sci. 2019 Nov 15;237:116950
pubmed: 31605709
Ann Clin Lab Sci. 2019 Sep;49(5):608-610
pubmed: 31611203
FEBS J. 2021 Jan;288(1):10-35
pubmed: 32910536
Tohoku J Exp Med. 2020;251(4):313-326
pubmed: 32779621
Mol Med Rep. 2018 Dec;18(6):5799-5806
pubmed: 30365083
Electrophoresis. 2002 Sep;23(19):3434-44
pubmed: 12373774
Am J Physiol Lung Cell Mol Physiol. 2011 May;300(5):L730-9
pubmed: 21398498
Mol Med Rep. 2017 Nov;16(5):6634-6641
pubmed: 28901418
Immunobiology. 2020 Sep;225(5):151997
pubmed: 32962817
Expert Rev Proteomics. 2018 Nov;15(11):923-935
pubmed: 30362838
Mol Omics. 2021 Feb 22;17(1):43-58
pubmed: 33073811
Biochim Biophys Acta Proteins Proteom. 2021 Feb;1869(2):140563
pubmed: 33176218
J Mol Endocrinol. 2018 Jul;61(1):47-56
pubmed: 29844093
Thorax. 2019 Mar;74(3):309-312
pubmed: 30244194
Pharmacol Rev. 2015;67(1):103-17
pubmed: 25395505
Monaldi Arch Chest Dis. 2020 Apr 30;90(2):
pubmed: 32362107
Curr Opin Genet Dev. 2009 Oct;19(5):476-83
pubmed: 19864126
Proteomics Clin Appl. 2014 Dec;8(11-12):932-50
pubmed: 25169739
Proteomics Clin Appl. 2019 Sep;13(5):e1900028
pubmed: 31119868
Am J Respir Crit Care Med. 2013 Sep 15;188(6):733-48
pubmed: 24032382
Am J Physiol Lung Cell Mol Physiol. 2019 Jun 1;316(6):L977-L989
pubmed: 30892076